# US 2012/0252846 A1 · Buccal, polar and non-polar spray or capsule containing drugs for treating pain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252846 A1
- Document ID: US20120252846A1
- Status: Published application
- Kind: A1
- Application number: 13/467,441
- Filed: 2012-05-09
- Published: 2012-10-04
- Earliest claimed: 1997-10-01
- Inventors: Harry A. Dugger, III
- Web page: https://patentgrep.com/patent/US20120252846A1

## CPC

- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 31/085: having an ether linkage to aromatic ring nuclear carbon
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/27: of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/421: 1,3-Oxazoles, e.g. pemoline, trimethadione
- A61K 31/433: Thidiazoles
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 38/13: Cyclosporins
- A61P 23/02: Local anaesthetics
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/36: Opioid-abuse
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.

## Claims

### Claim at position 1

1-55. (canceled)

### Claim 56

A method of treating pain in a human patient comprising:
providing an oral spray composition comprising fentanyl or a pharmaceutically acceptable salt thereof in an amount between 0.001 and 60 percent by weight of the total composition; and
a polar solvent in an amount between 30 and 99.69 percent by weight of the total composition; and
spraying the composition on the oral mucosa of the patient to provide transmucosal absorption of an amount of fentanyl through the oral mucosa of the patient sufficient to treat the patient's pain.

### Claim 57 (depends on 56)

The method of claim 56, the composition further comprising a flavoring agent in an amount between 0.1 and 10 percent by weight of the total composition.

### Claim 58 (depends on 57)

The method of claim 57, wherein the polar solvent is present in an amount between 37 and 98.58 percent by weight of the total composition, fentanyl or a pharmaceutically acceptable salt thereof is present in an amount between 0.005 and 55 percent by weight of the total composition, and the flavoring agent is present in an amount between 0.5 and 8 percent by weight of the total composition.

### Claim 59 (depends on 57)

The method of claim 57, wherein the polar solvent is present in an amount between 60.9 and 97.06 percent by weight of the total composition, fentanyl or a pharmaceutically acceptable salt thereof is present in an amount between 0.01 and 40 percent by weight of the total composition, and the flavoring agent is present in an amount between 0.75 and 7.5 percent by weight of the total composition.

### Claim 60 (depends on 56)

The method of claim 56, wherein the polar solvent comprises a polyethylene glycol having a molecular weight between 400 and 1000, a C2 to C8 mono- and polyalcohol, or a C7 to C18 alcohol of linear or branched configuration.

### Claim 61 (depends on 56)

The method of claim 56, wherein the polar solvent comprises aqueous polyethylene glycol.

### Claim 62 (depends on 56)

The method of claim 56, wherein the polar solvent comprises aqueous ethanol.

### Claim 63

A method of treating pain in a human patient comprising:
providing an oral spray composition comprising fentanyl or a pharmaceutically acceptable salt thereof in an amount between 0.005 and 55 percent by weight of the total composition; and
a non-polar solvent in an amount between 30 and 99.69 percent by weight of the total composition; and
spraying the composition on the oral mucosa of the patient to provide transmucosal absorption of an amount of fentanyl through the oral mucosa of the patient sufficient to treat the patient's pain.

### Claim 64 (depends on 63)

The method of claim 63, the composition further comprising a flavoring agent in an amount between 0.1 and 10 percent by weight of the total composition.

### Claim 65 (depends on 63)

The method of claim 63, wherein the solvent comprises a (C2-C24) fatty acid (C2-C6) ester, a C7-C18 hydrocarbon of linear or branched configuration, a C2-C6 alkanoyl ester, or a triglyceride of C2-C6 carboxylic acid.

### Claim 66 (depends on 65)

The method of claim 65, wherein the solvent comprises one or more fatty acid esters.
